Intelligence Profile
Research Papers
Research Papers and Clinical Trials
The research on bioidentical progesterone comes primarily from narrative reviews and position papers rather than large-scale clinical trials. The available evidence is limited, with most studies focusing on broader hormone replacement therapy topics rather than specifically examining bioidentical progesterone.
Key Research Papers
A 2025 narrative review published in the Journal of Clinical Medicine examined the use of estradiol and micronized progesterone as hormone replacement therapy, though specific details about study methodology and findings are not available from the title alone. This represents one of the more recent comprehensive reviews on the topic.
Position papers from medical societies, including a 2025 publication from the Polish Society of Menopause and Andropause in Menopause Review, have addressed the use of hormone therapies, though these focus more on clinical recommendations than original research data.
A 2024 systematic review and meta-analysis published in Human Reproduction Open examined progesterone safety, specifically looking at congenital anomalies after first-trimester dydrogesterone use, though this relates to pregnancy rather than menopausal hormone therapy.
Several broader reviews have been published recently, including perspectives on hormone replacement therapy in Frontiers in Global Women's Health (2024) and discussions of compounding hormone replacement therapy in the International Journal of Pharmaceutical Compounding (2024).
Clinical Trials
The clinical trial evidence for bioidentical progesterone is extremely limited. Only three relevant trials were identified:
A completed Phase 1 pharmacokinetic study (NCT00864214) evaluated bioidentical compounded estrogen cream and natural progesterone, focusing on how these compounds are processed by the body rather than clinical outcomes.
A Phase 4 study examining "physiologic restoration" (NCT04190927) has unknown status, limiting the availability of results.
A Phase 2 trial evaluating bioidentical hormones in early menopause (NCT00302731) was terminated, meaning it did not produce usable data.
Evidence Limitations
The research base for bioidentical progesterone is notably thin. Most available publications are narrative reviews, position papers, or studies examining broader hormone therapy patterns rather than controlled trials specifically testing bioidentical progesterone's safety and efficacy. The limited clinical trial data, with one terminated study and others focusing on pharmacokinetics rather than clinical outcomes, represents a significant gap in the evidence base.
This information is for educational purposes only and should not replace consultation with a healthcare provider for personalized medical advice.